• LXRP has global patents or patents-pending in more than 40 countries, including the U.S., Australia, China, the European Union and Canada
• Company is working through a C$250,000 budget for an 18-month collaborative research agreement with the National Research Council
• Licensing is a revenue generator, with LXRP offering to license its disruptive DehydraTECH™ technology in countries where it is patented or patent-pending

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is generating revenue and knowledge through both licensing of its IP portfolio and advancement of R&D projects. It already has patents and multiple patents-pending in more than 40 countries. It has received patent approvals in the U.S. and Australia for its DehydraTECH™ delivery technology (http://ibn.fm/6nDPP). Some patent applications have already reached the active patent investigation phase in China, the European Union and Canada.

LXRP is a technology disruptor for delivery of edible forms of cannabinoids. This Kelowna, British Columbia-based food bioscience company has developed a high absorption hemp oil formula, protein energy bars, exotic teas and coffee, beer and soft drinks, and capsules and mouth-melts. All of these products share qualities of high absorption and radically improved taste, as compared to other cannabis-related food products.

The Canadian Institutes of Health Research has secured $1.4 million in funding for Canadian cannabis research projects (http://ibn.fm/v8wNY). That will fund research ranging from the potential impacts of cannabis on driving, pregnancy, childhood health, youth mental health, indigenous populations and workplace health and safety (http://ibn.fm/iHOo1).

LXRP itself has signed a C$250,000 collaborative research agreement with the National Research Council (“NRC”) for an 18-month period to investigate opportunities and determine the best methods for processing lipophilic active agents within foods.

Licensing its intellectual property portfolio is a core revenue generation strategy for LXRP (http://ibn.fm/kik2R). For example, the company’s disruptive new DehydraTECH technology is available to be licensed in areas including processed foods, supplements, vitamins, drugs and cannabinoids. To prospective licensees, LXRP can eventually transition to a definitive fee for a structure agreement between itself and a new licensee.

The company makes its technology available on either a semi-exclusive or exclusive access basis that defines licensing by geographic region(s), for a set period of time and limited to specific product categories. LXRP has suggested that it will license DehydraTECH in any of the more than 40 countries globally where it is patented or patent-pending.

For more information, visit the company’s website at www.LexariaEnergy.com

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

• Cobalt demand set to increase substantially with the growth of electric vehicle use worldwide
• First Cobalt is focused on developing safer, more ethical mining resources in Canada
• Early results in 2018 exploration program produce positive results

Cobalt is a key component in lithium-ion batteries used to power electric vehicles (EVs) and has experienced a surge in demand on the back of recent developments in the automotive industry. China, with the largest automotive industry in the world, announced last year that it will require one in five new vehicles sold by 2025 to be powered by alternative sources other than fossil fuels. In July 2017, France and Britain followed suit by stating their intention to ban the sale of cars operating on fossil fuels by 2040. First Cobalt Corp. (TSX.V: FCC) (OTCQB: FTSSF) is well positioned to capitalize on the increasing cobalt demand by developing its mining interests in Ontario, Canada.

Much of the world’s cobalt sourcing currently faces real challenges, since it depends largely on the Democratic Republic of Congo (DRC), where child labor is common. First Cobalt offers a huge ethical advantage by developing cobalt sources in Canada, in addition to the potential of greatly helping to revitalize the nearby Canadian community of Cobalt, Ontario. The DRC has also experienced political unrest and instability for many years, and this climate is not conducive to investment. This is another reason that First Cobalt has made the strategic decision to focus its efforts on developing its Canadian mineral rights around the Cobalt Camp in Ontario.

Following the completion of a three-way merger in 2017, First Cobalt now has control over 10,000 hectares of land for prospecting. This area features more than 50 historic mines, including Bellellen, Keeley, Frontier, Drummond and Silver Banner. The company intends to explore these mines, which, based on historic analysis, have the potential to yield high-quality cobalt. First Cobalt also owns the only permitted cobalt extraction refinery in North America capable of producing battery materials.

On January 16, 2018, the company announced a $7 million exploration program for its Cobalt Camp properties in 2018. This will involve 26,500 meters of drilling to test different geological settings at 13 targets within the region. 2017 drill programs revealed that cobalt occurs as different styles of mineralization in the Cobalt Camp, largely due to different geographical settings. First Cobalt’s drilling program will test several prospective areas to determine near-surface mineralization potential.

The company’s early exploration and development efforts have produced positive results. On January 30, 2018, First Cobalt announced the completion of the first phase of its sampling program at its historic mining operations in the Cobalt Camp. More than 400 samples were collected from 14 muckpiles in both Cobalt North and Cobalt South. The company is currently evaluating the potential to generate early cash flow from processing these historic resources.

On February 5, 2018, First Cobalt announced positive drill results from the historic Keeley mine, intersecting over 30 meters of disseminated cobalt mineralization. These included evidence of anomalous cobalt grading 0.043 percent cobalt starting 15 meters from the surface. Results also include 15.7 meters of 0.12 percent cobalt, including 6.2 meters at 0.21 percent cobalt, which reflect similar mineralization in surface grab samples. These results provide evidence of a broad zone of mineralization extending over a strike length of 350 meters outside of the historically mined veins. These broad zones, while lower in grade, are targeted for their potential as large-scale, bulk tonnage future operations.

These early positive results augur well for the outcome of the company’s drilling program. With experienced teams and seasoned management at the helm, First Cobalt is well positioned to capitalize on its exploration program and develop its mineral interest to meet the rising global demand for cobalt.

For more information, visit the company’s website at www.FirstCobalt.com

Let us hear your thoughts: First Cobalt Corp. Message Board

• Company’s revenues have grown 600 percent during past year
• Growing AI, big data industries anticipate enormous increases in less than a decade
• Company turns ‘machine learning’ into beneficial interface with people

More than two years have passed since IBM acquired The Weather Company, the pioneering forecasting and technology company that launched a nationwide TV weather network and established data sets used by millions of people to make decisions about what they are going to do on a given day. When the company was formed in 1982 as The Weather Channel, it likely couldn’t forecast its own future — that one day it would be a staple in the tech giant’s Data and Analytics Platform business unit. But as artificial intelligence breakthroughs make the science of predicting the future more reality than fiction, companies like AnalytixInsight, Inc. (TSX.V: ALY) (OTCQB: ATIXF) are bending that science to the wills of millions of market investors who hope for a heads up on corporate activities such as dividend cuts, as well as the stock swings that may accompany news of earnings reports, consumer trends and political machinations.

During the decades before AnalytixInsight was incorporated, artificial intelligence was the stuff of science fiction, portrayed as the ascendancy of machines to a position of power over humanity. While AI does empower robotics platforms to perform some actions independently, the modern reality of artificial intelligence is that humans supply computers with data and then computers reciprocate by supplying humans with extrapolated knowledge people can use to inform their choices. As with commuters who decide what to wear or where to travel or how to prepare their homes based on predictive weather models, AnalytixInsight’s AI platform, named CapitalCube, helps people improve their decision-making on whether to buy or sell, when to do it and for how much.

CapitalCube is a ‘machine learning’ product that analyzes huge volumes of data and turns numbers into actions with its hyper-personalized services. The product’s predictive analytics and peer analysis features accompany 3,000 reports a day on some 50,000 companies’ dividend strength and accounting reports, among other things. CapitalCube also links to another AnalytixInsight subsidiary — Marketwall — that creates software for mobile devices, allowing users to receive the power of the platforms’ peer analyses wherever they may be. The Toronto, Canada-based company expects to employ blockchain technology to provide security in any financial transactions that may take place through the platforms. Another subsidiary, Euclides Technologies, helps companies search and evaluate inefficient operations within their own walls and attempt solutions to employee performance and other quality control concerns.

A recent content agreement with the Thomson Reuters news agency is likely to boost AnalytixInsight’s brand. Thomson Reuters is the world’s leading source of news and information for professional markets. AnalytixInsight has added Thomson Reuters as a content distribution partner, which paves the way for CapitalCube’s analysis reports to be available on Thompson Reuters terminals to brokers across North America.

In its latest update on human-technology interaction, market intelligence company Tractica issued a forecast that annual worldwide AI revenue will grow from $3.2 billion in 2016 to $89.8 billion by 2025 (http://ibn.fm/yy6Ga), marking an increase of nearly 3,000 percent in less than a decade. Analysis portal Statista.com estimates that the larger-scale revenues of the global big data industries amount to just under $34 billion now (http://ibn.fm/Wt2vz), with the capacity to grow to nearly $80 billion over the next five years. SNS Research believes that global big data revenues now lie at over $57 billion (http://ibn.fm/IFwnH), with a forecast CAGR of about 10 percent during the next three years amounting to about $76 billion by the end of 2020. Despite the disparities in revenue modeling, the researchers all agree that AI and the larger big data industries are growing and profitable.

AnalytixInsight’s last quarterly report showed record revenues of $1.7 million, a 600 percent increase over the same period in the previous year.

For more information, visit the company’s website at www.AnalytixInsight.com

Let us hear your thoughts: AnalytixInsight Inc. Message Board

• The tide of cannabis legalization continues to rise
• Medical cannabis market on pace to hit $56 billion in seven years
• Company’s proprietary technology improves the bioavailability of cannabinoids

With the passage of laws permitting medicinal use of cannabis in at least 32 U.S. jurisdictions and Canada, producers of cannabinoids for medical purposes are racing to improve delivery methods for their formulations. Cannabinoids, such as cannabidiol (CBD), are hydrophobic (literally, afraid of water). In practice, this means they do not dissolve or emulsify readily in water, which may seem to pose a problem, since, by composition, the human body is more than half water. Yet, paradoxically, for a drug to be readily absorbed, it must be largely hydrophobic, yet not completely so. It must, to some extent, dissolve in water. As a result, new, patented technology from Pressure BioSciences Inc. (OTCQB: PBIO) may provide the ideal transport for CBD and other cannabinoids. PBIO’s Ultra Shear Technology (“UST”) has the capacity to develop water-soluble nanoemulsions that can be employed to improve the bioavailability of cannabinoids.

Emulsions are mixtures of two or more liquids (e.g., oils in water) that cannot be blended into each other without the addition of chemicals called emulsifiers (e.g., surfactants). Emulsions are used in multiple everyday products, including food, medical products, pharmaceuticals, nutraceuticals, cosmetics, industrial lubricants, and even cannabis oil extracts (e.g., CBD). Nanoemulsions have been shown to have improved absorption while providing higher bioavailability, greater stability and other advantages, when compared to the standard, much larger macro- and micro-emulsions.

Nanoemulsions offer an advanced mode of drug delivery that’s expected to improve the bioavailability of a wide range of active agents. These nano-sized emulsions, in which two immiscible liquids are usually combined to form a single phase by means of an emulsifying agent that combines surfactant and co-surfactant, typically have droplet sizes that fall in the 20–200 nanometer range. It would take 10 million nanometers to cover a length of one centimeter (about 0.4 inches).

Interestingly, PBIO believes that its patented UST may be able to make commercial-scale nanoemulsions that would require far less emulsifying agents than current methods, perhaps even none. Emulsifying agents are chemicals; some are natural, some are not. With consumer demands for non-additive natural products, the availability of nanoemulsions that require little or no chemical emulsifiers should be well received by consumers and manufactures alike, and rewarded by shareholders.

Late last year, PBIO announced a partnership with Phasex Corporation. The aim of the collaboration is to combine PBIO’s patented UST and Phasex’s supercritical fluid (“SCF”)-based processing methods to enable the development of stable, water-soluble nanoemulsions of nutraceuticals, including CBD-enriched plant oil. Phasex is a pioneer in the development of SCF-based toll processors, which are used for extracting, purifying, recrystallizing and fractionating a wide range of polymers, natural extracts and other chemicals.

Complementing Phasex’s SCF extraction technology with PBIO’s UST makes a great deal of commercial sense. Currently, there is a market for new methods of turning hydrophobic extracts into stable, water-soluble formulations. UST offers the potential to solve that problem by producing stable nanoemulsions of oil-like products in water. The range of commercial applications is extensive and includes inks, industrial lubricants, cosmetics, pharmaceuticals and nutraceuticals, as well as medically important plant oil extracts such as CBD. UST utilizes ultra-high pressure-driven fluid dynamic shear forces, combined with controlled temperatures, to engender homogenization.

Data from scientific studies indicate that nanoemulsions of nutraceuticals and pharmaceuticals may exhibit improved absorption, higher bioavailability, greater stability and lower levels of stabilizing additives (surfactants) when compared to the larger droplet sizes resulting from current emulsion processes. Because of these significant advantages, nanoemulsions are currently the focus of many research efforts worldwide. In this field, the PBIO-Phasex joint venture is poised to break new ground. Combining Phasex’s SCF extraction methodology with PBIO’s disruptive drug delivery technology may signal the genesis of an entirely new paradigm in therapeutic treatments.

The global medical marijuana market is set to reach a value of $55.8 billion by 2025, according to a new report by Grand View Research, Inc. As it expands, the demand for enabling medical technologies, such as UST, is set to rise. PBIO, it seems, is about to thrive in the brave new world of cannabis liberalization.

For more information, visit the company’s website at www.PressureBioSciences.com

• Proposed legislation would be more moderate than a current legalization initiative but allow more concessions than a more conservative bill submitted this season
• Jeremy Roberts is confident the yet undrafted bill will be ready for consistent debate before the end of the current legislative session on March 8
• Cannabis is illegal in Utah, with only one exception: non-psychoactive medical CBD oil extract is allowed for patients suffering from severe epilepsy

A medical cannabis bill that would advocate a more moderate approach and would “bridge the gap” between two very different legalization initiatives currently underway, has every chance to be successful, according to Medical Cannabis Payment Solutions (OTC: REFG) CEO Jeremy Roberts, quoted by the Deseret News (http://ibn.fm/ujXBR). Roberts, who is also a member of the Utah Republican Party, discussed the matter with Rep. Lee Perry, who is planning on coming up with a “workable medical marijuana program in the state.” While the bill has not yet been formally drafted, with Perry still gathering input on language and contents, Roberts is confident that the initiative will be ready in time to be debated before the end of the legislative session on March 8.

Leveraging his experience as CEO of a merchant processing pioneer in the medical cannabis industry, Roberts said he met with several interested lawmakers in recent months to discuss what would be a “reasonable program” with appropriate controls in place to allow patients access to marijuana-based medication they need. Talks even focused on aspects of current marijuana legislation in other states, to determine which policies would make the most sense for Utah.

Cannabis is illegal in Utah, with the exception of a non-psychoactive medical CBD oil extract for patients with severe epilepsy. Advocates of medical marijuana legalization for people with serious medical conditions are rallying for a state-wide ballot sometime this year, an initiative that enjoys overwhelming support. About 76 percent of Utah voters are in favor of the initiative, according to a January survey by The Salt Lake Tribune and the Hinkley Institute of Politics with the University of Utah (http://ibn.fm/BTp4i). Opponents of the initiative, including Perry and Roberts, say the ballot goes further than most people realize and would basically provide backdoor access to the equivalent of a recreational program.

On the other side, Rep. Brad Daw has introduced a package of bills on medical marijuana which would allow terminally ill patients to try the substance and would have the state grow its own plant. Roberts believes the legislation proposed by Daw this session is too conservative, and not too different from the “ultra-conservative” initiatives that the legislature has come up with up to this point.

Lawmakers know that they need to pass a medical marijuana bill but “they haven’t been given a good option” so far, Roberts said. The Medical Cannabis Payment Solutions CEO is confident that what Perry will come up with be viewed as a better and more moderate option which the caucuses are going to love. The bill will most likely start by allowing unrestricted access to CBD oil to all patients who need it, and broad access to marijuana for terminally ill patients. Gradually, the bill will allow for higher ratios of THC to CBD for certain categories of patients, but it will most likely not allow access to the whole plant at any point, Roberts explained.

In a separate interview with Jane King of SCN Corporate Connect (http://ibn.fm/7cJh8), Roberts talked about his company’s commitment to regulatory compliance, as opposed to other companies in the industry which would rather “walk away” than put in the work to meet the federal government’s very strict guidelines and regulations. He said that part of his activity in Washington DC includes working with the authorities to show that “people actually can and are willing to comply with the regulations they put forth.”

Roberts also briefly discussed his company’s fully secure, state-of-the-art services to the medical marijuana sector, in particular its ability to track sales and tax collection from the moment when a buyer enters the vendors’ establishment, the purchases made, all the way through the payment of taxes. This functionality “hasn’t existed up until we’ve come to the marketplace, and we can actually show the provenance of funds in that market,” he said.

Medical Cannabis Payment Solutions brought to the market the first and only comprehensive card processing service. Via Green, a proprietary payment system that was launched earlier in January 2018, the company aims to offer a “cure for the banking nightmare cannabis establishments face,” according to Roberts. The platform has full merchant account functionality that allows for repeat billing, online sales, client management and 100 percent secure electronic payments. The system is also fully compliant with Financial Crimes Enforcement Network (FinCen) regulations and parameters for financial institutions serving the medical cannabis sector.

For more information, visit the company’s website at www.REFG.co

Let us hear your thoughts: Medical Cannabis Payment Solutions Message Board

• Update highlights proposed acquisitions, product development and growing IP portfolio
• Three new patent filings join established global rights to other patented technologies
• Innovative transdermal delivery technology increases bioavailability of cannabinoids
• Global cannabis market projected to reach $31.4 billion by 2021

Pivot Pharmaceuticals Inc. (OTCQB: PVOTF) has provided investors an update covering a number of recent achievements and ongoing activities, including the company’s proposed acquisitions of ERS Holdings, LLC and Thrudermic, LLC; its ongoing product development efforts; its growing IP portfolio; its termination of a previously announced standstill agreement; out-licensing of its IP; and its engagement of an established European distribution partner (http://ibn.fm/GZfrU). In a news release, Dr. Patrick Frankham, CEO of Pivot, stated, “We are overwhelmed by interested companies who now understand that derivatives and superior formulations will improve cannabis product experience and healthy outcomes.”

Based in Vancouver, Canada, Pivot Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using proprietary drug delivery platform technologies. By developing and commercializing a number of pharmaceutical-grade formulations for cannabinoid-based consumer health care products, Pivot Pharmaceuticals is positioning itself to capitalize on the impressive growth of the cannabis market. According to market research company Brightfield Group, the marijuana market will experience a CAGR of 60 percent to reach $31.4 billion by 2021 (http://ibn.fm/8ePj2).

As part of its overall growth strategy, Pivot Pharmaceuticals recently filed three provisional patents for cannabinoid-based product delivery with the U.S. Patent and Trademark Office, according to a company press release (http://ibn.fm/tcV0W) issued on February 1, 2018. Its three patents cover:

• Transdermal nanotechnology delivery of cannabis using patches and creams
• Mucus topical cannabis delivery through buccal, nasal, vaginal and anal areas using a gel, mouthwash or suppository
• Inhalation delivery of cannabis for topic or systemic applications

These latest provisional patent filings join an established number of global rights to topical, oral, transdermal, food and beverage patented technologies that Pivot has already secured.

A case in point is Pivot’s recent acquisition of the BiPhasix™ Transdermal Drug Delivery technology for the delivery of cannabinoids. Oral delivery of cannabinoids can produce inconsistent absorption efficiencies and unfavorable side effects, while topical delivery technologies often suffer from weak formulation issues. By contrast, transdermal delivery has greater potential to produce a more favorable outcome without the negative side effects and absorption issues. Another benefit of transdermal delivery is that it enables patients to apply medication over a prolonged period with fewer side effects than with other methods of delivery. The BiPhasix™ delivery system, thoroughly tested in clinical trials approved by the FDA and EMA, was demonstrated to enhance the bioavailability of drugs and to improve clinical outcomes.

Pivot Pharmaceuticals also created subsidiary Pivot Green Stream Health Solutions Inc. to focus on improving the bioavailability of cannabinoid-based pharmaceuticals. Pivot Green Stream will develop natural cannabinoid-based health products that qualify for the Natural Health Product (NHP) designation conferred by Health Canada.

In addition, Pivot has acquired the global rights from Solmic GmbH for the development and commercialization of the Solmic Solubilization Technology Platform. This formulation technology provides significantly higher bioavailability of active ingredients while masking unpleasant tastes and smells. This oral delivery platform greatly increases uptake of fat-soluble ingredients from the gut into the blood system, resulting in increased bioavailability.

The company has several products in its development pipeline which target cancer supportive care, pain and inflammation, dermatology and eye disease. They include PGS-N005, a cannabinoid-based topical cream to treat female sexual dysfunction. This formulation will treat hypoactive sexual desire disorder, aimed specifically at peri-menopausal, menopausal and post-menopausal women with a decline in sexual desire and response. It is estimated that up to 63 percent of women in the United States may be affected by this disorder, with the female sexual dysfunction market estimated to exceed $4 billion.

Pivot Pharmaceuticals has a seasoned management team with extensive clinical, product development, commercial and financial experience. The company has positioned itself to be a crucial vertical in the cannabis industry, with a focus on biotechnological development. As part of its business strategy, Pivot works with licensed producers (LPs) and licensed dealers (LDs) to bring new therapies to the market.

For more information, visit the company’s website at www.PivotPharma.com

• WHO recommends that CBD not be a controlled substance
• Operations at various points in the cannabis and industrial hemp industries
• Launch of new products for convenience stores

Two major trends are fostering the success Marijuana Company of America, Inc. (OTC: MCOA) is having. With 29 states and the District of Columbia now permitting the use of cannabis for either medicinal or recreational purposes and public stigma surrounding cannabinoids fast fading, the cannabis and cannabidiol (CBD) industry is moving toward a maturity that will make it an economic sector to be reckoned with. At the same time, an increasingly health-conscious American public is discovering the benefits of hemp-derived CBD, which, unlike delta-9-tetrahydrocannabinol (THC), is devoid of psychotropic properties.

The company, established in 2015 in California by Don Steinberg and Charles Larsen, is set to execute its vision of creating a diverse portfolio of cannabis- and hemp-based businesses. MCOA has already established a commanding presence at various points in the cannabis and industrial hemp markets, as well as the related services supply chains.

Meanwhile, MCOA’s wholly owned subsidiary, hempSMART™, Inc., continues its mission of bringing high quality hemp-derived CBD-based products to market through its affiliate marketing program. Its patent-pending product, hempSMART Brain, is designed to provide safe and effective support of healthy brain function, and its recently launched hempSMART Full Spectrum Drops offer a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. Moreover, in December 2017, MCOA announced the debut of a new personal care product: hempSMART Pain Cream (http://ibn.fm/poJ6c), and hempSMART Pain Capsules are formulated with 10mg of full spectrum, non-psychoactive CBD per serving, derived from industrial hemp as the core ingredient, which, along with a proprietary blend of other natural ingredients, delivers an all-natural formulation.

MCOA has also partnered with the founders of HoneyB Healthy Living to develop Convenient Hemp Mart, LLC’s BeniHemp branded products targeting convenience stores, according to a recent news release (http://ibn.fm/z7rTU). MCOA has invested $100,000 into the start-up project in exchange for a 25 percent equity stake.

Now that the Expert Committee on Drug Dependence (ECDD) of the World Health Organization (WHO) has officially recommended that ‘cannabis compound cannabidiol (CBD) not be internationally scheduled as a controlled substance’ (http://ibn.fm/mlSXz), MCOA looks set for success in the fast developing cannabis and industrial hemp CBD markets.

For more information, visit the company’s website at www.MarijuanaCompanyofAmerica.com

Let us hear your thoughts: Marijuana Company of America, Inc. Message Board

• U.S. heading for number three spot in global LNG exports
• PGAS to leverage shipping expertise to enter U.S. LNG export market
• PGAS operates crude oil tanker fleet in Mediterranean and West Africa

Now that the U.S. has copped the number one spot in global natural gas production, the country is moving quickly to join the frontrunners in global LNG exports. A feature in the Houston Chronicle (http://ibn.fm/fRFNn), citing U.S. Department of Energy data, ‘projects that LNG production capacity will quadruple by the end of 2019, making the (U.S.) the largest source of LNG after Qatar and Australia.’ Much of the exported LNG will leave the U.S. from Texas, where Petrogress, Inc. (OTC: PGAS) has widened its international footprint by establishing a subsidiary. The company plans to leverage its expertise in oil transportation and shipping, gained in the tough Mediterranean and West African markets, to gain a competitive advantage as the U.S. heads for global dominance in the natural gas market.

Through its Texas subsidiary, Petrogress Oil & Gas Energy Inc., PGAS is poised to capitalize on the seismic shifts transforming the natural gas industry in the U.S. Just a few years ago, the country was heavily reliant on imports of natural gas and was expected to remain that way for the near future. However, the shale revolution reversed that prospect, and the U.S. dispatched its first exports of LNG in February 2016 (http://ibn.fm/eqFPX), according to the American Petroleum Institute (API). Buoyed by growing exports to Mexico, the U.S. is currently the world’s largest natural gas producer, a position it took from Russia in 2009. This means that, since 2008, when output was 55 billion cubic feet per day (Bcf/d), U.S. natural gas production has increased by 32 percent, reaching 72.5 Bcf/d in 2016.

PGAS has set up a number of American business units to join the export extravaganza. Petrogress Oil & Gas Energy Inc., in Texas, will handle trading and logistics, while a sister subsidiary incorporated in Delaware, Navigas Carriers Inc., will manage natural gas activities. Through Navigas Carriers, PGAS plans to begin leasing LNG tankers to enter this lucrative LNG export market. To complement the shipping operations, Petrogress Oil & Gas Energy Inc. will actively seek opportunities in operating and developing natural gas production and transmission facilities, along with LNG processing, in the U.S. It will also explore opportunities for developing refinery operations in North and West Africa, and for the transport and sales of LNG in Europe.

From its international offices in Piraeus, Greece, PGAS will oversee its U.S. operations as well as its Mediterranean and West African businesses. For some time, the company has been successfully operating as a fully integrated international merchant of petroleum products, focusing on the supply and trade of light petroleum fuel oil (LPFO), refined oil products and other petrochemical products to local refineries in those regions.

As a holding company, PGAS provides its services through five wholly owned subsidiaries: Petrogres Co. Limited, which provides management of crude oil purchases and sales; Petronav Carriers LLC, which manages day-to-day operations of its beneficially-owned affiliated tanker fleet, currently consisting of four vessels; Petrogress Int’l LLC, a holding company for subsidiaries currently conducting business in Cyprus and Ghana; Petrogress Oil & Gas Energy Inc.; and its U.S. export shipping unit, Navigas Carriers Inc.

For more information, visit the company’s website at www.PetrogressInc.com

Let us hear your thoughts: Petrogress, Inc. Message Board

• ETST intends to make 2018 its breakout year, seeks uplisting to the OTCQB Venture Market
• Company manufactures using European CO2 extraction process with organically grown, unfiltered industrial hemp
• ETST engages a new distributor to market revamped product line to major retailers, also adds several new members to its executive team

On February 13, Earth Science Tech, Inc. (OTC: ETST) officially launched its High Grade Full Spectrum Cannabinoids products and a corresponding marketing strategy, as the company detailed in a recent news release (http://ibn.fm/Q4pQN). Additionally, it signed a distribution agreement with Mr. Checkout to market its revamped product line to major retailers and stores, such as Walmart, Target and Walgreens (http://ibn.fm/BgSyv).

The revamped line consists of industrial hemp product formulated as a cannabinoid complex, which is naturally occurring in the industrial hemp plant and is rich in terpenes and saponins. The company’s products are mixed, bottled and packaged in the U.S., and reorders are currently being accepted online. The line appears in modern and edgy packaging.

Based in Florida, ETST markets high-purity, high-grade hemp cannabidiol (CBD) oil. It is 100 percent natural and organic. The company has three wholly-owned subsidiaries: Earth Science Pharmaceutical markets low-cost, non-invasive medical devices for the detection of sexually transmitted diseases (STDs); Cannabis Therapeutics is an emerging biotechnology company; and KannaBidioiD focuses on the recreational space with its hemp and Kanna blends.

ETST recently strengthened its core executive team (http://ibn.fm/kTUuA) through the addition of Jill Buzan as chief sales officer, Wendell Hecker as chief financial officer and Gabriel Aviles as chief learning officer. The company expects the moves to foster bottom line growth in 2018.

In a news release, Nickolas S. Tabraue, COO and president of ETST, said, “Between appointing a new Chief Sales Officer, launching revamped industrial hemp products with fresh branding and marketing strategies, and our new distributor, Mr. Checkout, we are on track for a record-setting revenue month.” He added that the company intends to make 2018 its breakout year, for which it is laying a strong foundation in the first quarter.

The company also announced that it has completed the paperwork for its uplisting to the OTCQB Venture Market later this year.

For more information, visit the company’s website at www.EarthScienceTech.com

• KBSF, through subsidiaries, operates more than 50 stores in China and also sells its line to multi-brand retailers
• Company is vertically-integrated – designing, marketing, manufacturing and selling its line of men’s footwear, apparel and accessories while targeting style-conscious urban males
• China-based company offers line of menswear that is practical, yet modern and stylish, enabling the client to express his personality through his clothes

KBS Fashion Group Limited (NASDAQ: KBSF) has named Keyan Yan its new CEO and president (http://ibn.fm/FLC2N). He continues to serve as board chairman of the company. The size of the board was reduced to seven.

Xiaowen Zheng tendered his resignation as CEO, president and director of the company, but KBSF said that this was not a result of any disagreement or dispute with the company or its management regarding any matters relating to operations, policies or practices.

China-based KBSF is a fully-integrated casual menswear company that, through its subsidiaries, designs, manufactures, markets and sells its own line of menswear. It targets urban males in the 20-40 age range with apparel, footwear and accessories. KBSF operates over 50 KBS stores and sells via a number of multi-brand stores.

The company is focused on the practical and “keep best style” concept in fashion design. It offers clothes in modern and colorful contemporary styles. The company says that the fashion offered by KBSF is designed for the stylish man who wishes to show his personality through his clothes.

For more information, visit the company’s website at www.KBSFashion.com